Skip to content
AnalystLens

Exelixis 8-K Report, Corporate Update (Oct 15, 2024)

Reports
Other Events
Filing Date
Filed October 15, 2024
Period End
October 15, 2024
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Dec ’19Dec ’19
  3. Leadership change8-K · May ’22May ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 8-K filed October 15, 2024. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. (Exelixis) reported in this Form 8-K, filed under Item 8.01 (Other Events), that the U.S. District Court for the District of Delaware issued a ruling in its two consolidated patent lawsuits against MSN Pharmaceuticals, Inc. (together with certain affiliates, including MSN Laboratories Private Limited, referred to as MSN).

The court rejected MSN's invalidity challenge to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, which expire January 15, 2030. MSN had previously stipulated that its proposed Abbreviated New Drug Application (ANDA) product infringes these patents. The court also found that Exelixis' U.S. Patent No. 11,298,349 is not invalid and that MSN's proposed ANDA product does not infringe it; this patent expires February 10, 2032.

The court asked the parties to jointly submit a final judgment reflecting the opinion by October 22, 2024. Based on the ruling, the effective date of any final FDA approval of MSN's ANDA shall not be earlier than January 15, 2030, the expiration date of the three patents that were upheld. The filing includes forward-looking statements, including on the potential timing of MSN's commercial launch of its proposed generic product in the United States, and refers readers to the Risk Factors sections of Exelixis' most recent Form 10-K and subsequent Forms 10-Q for relevant risks.

Key Highlights

  1. Delaware District Court rejected MSN's invalidity challenge to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, which expire January 15, 2030
  2. MSN had previously stipulated that its proposed ANDA product infringes these three patents
  3. Court found U.S. Patent No. 11,298,349 not invalid and MSN's proposed ANDA product does not infringe it; this patent expires February 10, 2032
  4. Court requested the parties jointly submit a final judgment reflecting the opinion by October 22, 2024
  5. Effective date of any final FDA approval of MSN's ANDA shall not be earlier than January 15, 2030
  6. Filing contains forward-looking statements on the potential timing of MSN's U.S. generic launch

Frequently Asked Questions

  1. What did the court decide in the MSN patent litigation?

    The U.S. District Court for the District of Delaware rejected MSN's invalidity challenge to three Exelixis patents (Nos. 11,091,439, 11,091,440 and 11,098,015), found that another Exelixis patent (No. 11,298,349) is not invalid, and ruled that MSN's proposed ANDA product does not infringe that patent.

  2. When do the patents at issue expire?

    U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 expire January 15, 2030. U.S. Patent No. 11,298,349 expires February 10, 2032.

  3. When could MSN's generic product receive FDA approval?

    According to the filing, based on the court's opinion, the effective date of any final FDA approval of MSN's ANDA shall not be a date earlier than January 15, 2030.

  4. What happens next in the case?

    The Delaware District Court requested that the parties jointly submit a final judgment reflecting the opinion by October 22, 2024.